These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6358810)

  • 21. Influence of exogenous glycosaminoglycans on growth and glycosaminoglycan synthesis of cultured human diploid fibroblasts (WI-38).
    Schachtschabel DO; Wever J; Sluke G; Wever G
    Z Gerontol; 1979; 12(1):19-26. PubMed ID: 433377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates.
    Casu B; Johnson EA; Mantovani M; Mulloy B; Oreste P; Pescador R; Prino G; Torri G; Zoppetti G
    Arzneimittelforschung; 1983; 33(1):135-42. PubMed ID: 6219676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cell proliferation and protease activity by cartilage factors and heparin.
    Hatcher VB; Tsien G; Oberman MS; Burk PG
    J Supramol Struct; 1980; 14(1):33-46. PubMed ID: 7012450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides.
    Bazin HG; Marques MA; Owens AP; Linhardt RJ; Crutcher KA
    Biochemistry; 2002 Jun; 41(25):8203-11. PubMed ID: 12069613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1979 Sep; 586(3):584-93. PubMed ID: 476156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
    Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
    Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulant properties in vitro of heparan sulphates.
    Hubbard AR; Jennings CA; Barrowcliffe TW
    Thromb Res; 1984 Sep; 35(5):567-76. PubMed ID: 6237461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance.
    Clarke D; Katoh O; Gibbs RV; Griffiths SD; Gordon MY
    Cytokine; 1995 May; 7(4):325-30. PubMed ID: 8589262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure and biological activity of heparin and other glycosaminoglycans.
    Casu B
    Pharmacol Res Commun; 1979 Jan; 11(1):1-18. PubMed ID: 370843
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of the cleavage sites resulting from enzymatic inactivation of human antithrombin III by Crotalus adamanteus proteinase II in the the presence and absence of heparin.
    Kress LF; Catanese JJ
    Biochemistry; 1981 Dec; 20(26):7432-8. PubMed ID: 7034776
    [No Abstract]   [Full Text] [Related]  

  • 33. Probing the heparin-binding domain of human antithrombin III with V8 protease.
    Liu CS; Chang JY
    Eur J Biochem; 1987 Sep; 167(2):247-52. PubMed ID: 3305015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antithrombin III].
    Boyer-Neumann C; Wolf M; Larrieu MJ
    Ann Biol Clin (Paris); 1987; 45(2):175-80. PubMed ID: 3619143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin binding and protease inhibitor activity of chemically modified antithrombin III.
    Blackburn MN; Smith RL; Sibley CC; Johnson VA
    Ann N Y Acad Sci; 1981; 370():700-7. PubMed ID: 6791550
    [No Abstract]   [Full Text] [Related]  

  • 37. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
    Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
    Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The heparins: structure and pharmacology].
    Choay J
    Rev Prat; 1988 May; 38(15):917-24. PubMed ID: 2839891
    [No Abstract]   [Full Text] [Related]  

  • 39. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathogenesis and prevention of atherosclerosis.
    Hässig A; Wen-Xi L; Stampfli K
    Med Hypotheses; 1996 Nov; 47(5):409-12. PubMed ID: 8951806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.